NEWS RELEASE

NIPPON SHINYAKU CO., LTD.

May 12, 2021

VILTEPSO® injection Long-Term Clinical Trial Data to be Presented at the PPMD 2021 Virtual Annual Conference

Kyoto, Japan, May 12, 2021 – Nippon Shinyaku Co., LTD. (Nippon Shinyaku; Headquarters, Kyoto; President, Shigenobu Maekawa) announced today that new, long-term efficacy and safety data (interim analysis at 109 weeks) from the open-label extension of a Phase 2 study of VILTEPSO® injection will be presented at the PPMD 2021 Annual Conference being held virtually from June 23-26 by NS Pharma, Inc. (President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd.

This VILTEPSO data to be presented at the PPMD Annual Conference represents one of the longest treatment times with exon-skipping therapy reported to date. In addition to this Phase 2 open-label extension study, we are conducting the confirmatory Phase 3 RACER53 trial.

About VILTEPSO

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. VILTEPSO received marketing authorization under an accelerated approval pathway in Japan in March 2020 and became commercially available in Japan in May of the same year. In the United States, it received accelerated approval from the US Food and Drug Administration (FDA) in August 2020 and has marketed through NS Pharma, Inc.

About NS Pharma, Inc.

NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information, please visit http://www.nspharma.com. NS Pharma is a registered trademark of the Nippon Shinyaku group of companies.

Contact

Corporate Communications Dept., Nippon Shinyaku Co., Ltd.
FAX: +81-75-321-9128